GURU.Markets stock price, segment price, and overall market index valuation
The company's share price MIRA Pharmaceuticals
MIRA Pharmaceuticals is a biopharmaceutical company developing cannabinoid-based drugs. Its stock price is highly speculative and driven by news of preclinical and clinical trials.
Share prices of companies in the market segment - Narco farm
MIRA Pharmaceuticals is a biopharmaceutical company developing a new drug for the treatment of anxiety and cognitive impairment, a synthetic analogue of cannabidiol. We have classified it as a "Narco-Pharma" company. The chart below shows how investors assess the medical potential of cannabinoids.
Broad Market Index - GURU.Markets
MIRA Pharmaceuticals is a biopharmaceutical company developing synthetic cannabinoid-based drugs for the treatment of neurological and psychiatric disorders. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the market.
Change in the price of a company, segment, and market as a whole per day
MIRA - Daily change in the company's share price MIRA Pharmaceuticals
MIRA Pharmaceuticals' daily share price fluctuations reflect the extreme volatility inherent in biotech companies working with cannabinoids. This metric measures the company's sensitivity to research data and regulatory announcements.
Daily change in the price of a set of shares in a market segment - Narco farm
MIRA Pharmaceuticals, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with MIRA, a company focused on cannabinoids, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
MIRA Pharmaceuticals develops cannabinoid-based medications without psychoactive effects. The company operates at the intersection of two volatile sectors: biotech and cannabis. Its shares respond to scientific and regulatory news, adding unique dynamics to the market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization MIRA Pharmaceuticals
MIRA Pharmaceuticals' year-to-date performance is a story of developing a new generation of drugs targeting cannabinoid receptors. Its market capitalization over the next 12 months depends entirely on progress in preclinical research. The success of its synthetic THC analogues could offer new treatments without psychoactive side effects.
Annual dynamics of market capitalization of the market segment - Narco farm
As an early-stage biotech company, MIRA is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its cannabinoid-based drugs. Its stock price will reflect investors' speculative faith in its R&D.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
MIRA Pharmaceuticals is a very small and highly speculative biotech company. Its stock price has nothing to do with fundamentals or the economy, but is driven by news of trials and investor confidence in the potential of its developments, making it a high-risk bet.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization MIRA Pharmaceuticals
MIRA Pharmaceuticals develops cannabinoid-based drugs. Its monthly performance is entirely dependent on progress in its preclinical and clinical programs. News about research results and interactions with the FDA are the main drivers of its value.
Monthly dynamics of market capitalization of the market segment - Narco farm
This chart reflects the dynamics of the biotech sector, particularly the psychedelic medicine segment. For MIRA, an early-stage company, this is the backdrop. Its volatile movements demonstrate how investor expectations surrounding breakthroughs in mental health treatments are impacting the entire industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
MIRA Pharmaceuticals is a biopharmaceutical company developing cannabinoid-based drugs. Its future depends on clinical data and the regulatory environment for such substances. The landscape of the cannabinoid biotech sector reflects both the scientific interest and the legal barriers that affect companies like MIRA.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization MIRA Pharmaceuticals
MIRA Pharmaceuticals, which develops synthetic cannabinoid analogues for the treatment of neurological disorders, is experiencing high volatility. Its weekly share price performance is a sharp reaction to news about the progress of preclinical and clinical trials, as well as changes in cannabis legislation.
Weekly dynamics of market capitalization of the market segment - Narco farm
MIRA Pharmaceuticals operates in the volatile biopharmaceutical sector, where investor sentiment often influences all players. M&A news or general regulatory changes can lift or derail the entire sector. The chart will show whether MIRA is moving with the industry or whether its specific developments are creating their own story.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
MIRA Pharmaceuticals, as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how MIRA shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
MIRA - Market capitalization of the company MIRA Pharmaceuticals
MIRA Pharmaceuticals' stock price is a speculative bet on the development of new psychoactive drugs. This company's market cap reflects investors' hopes for its research into synthetic cannabinoid analogues. Its volatility is a direct market reaction to each step toward clinical trials.
MIRA - Share of the company's market capitalization MIRA Pharmaceuticals within the market segment - Narco farm
MIRA Pharmaceuticals is a company developing drugs based on synthetic cannabinoid analogues without psychoactive effects. Its market share is based on this innovative approach. The chart shows how the market perceives its potential to create a new class of drugs for the treatment of neurological and psychiatric disorders.
Market capitalization of the market segment - Narco farm
MIRA Pharmaceuticals develops synthetic cannabinoid-based drugs for the treatment of neurological disorders. The chart below shows the pharmaceutical sector's market capitalization. This represents a risky but potentially breakthrough industry at the intersection of biotechnology and cannabis.
Market capitalization of all companies included in a broad market index - GURU.Markets
MIRA Pharmaceuticals develops drugs based on synthetic cannabinoid analogues, but without psychoactive effects, for the treatment of neurological disorders. Its market capitalization is a bet on this scientific approach. The chart below shows the weight of companies researching safe cannabis analogues.
Book value capitalization of the company, segment and market as a whole
MIRA - Book value capitalization of the company MIRA Pharmaceuticals
MIRA Pharmaceuticals' foundation is capital for the development of a new class of drugs. The company's book value consists of the intellectual property for a synthetic cannabinoid analogue with no psychoactive effects and funds for its preclinical and clinical trials. The chart below shows the financial basis for these innovative developments.
MIRA - Share of the company's book capitalization MIRA Pharmaceuticals within the market segment - Narco farm
MIRA Pharmaceuticals, which develops cannabinoid-based drugs, has key assets in the form of R&D laboratories. The S_BCap_Seg graph shows its share of scientific infrastructure, reflecting its focus on research in this new field of pharmacology.
Market segment balance sheet capitalization - Narco farm
MIRA Pharmaceuticals is a development-stage pharmaceutical company working with synthetic cannabinoid analogues. Its assets are patents and scientific data. The chart shows that its balance sheet is virtually asset-free, which is typical for a research-focused biotech company.
Book value of all companies included in the broad market index - GURU.Markets
MIRA Pharma's book value represents the scientific foundation for the creation of a new class of psychedelics. The company's assets include rights to synthetic cannabinoid analogues and capital for their preclinical and clinical trials. This material base is aimed at developing drugs without undesirable side effects for the treatment of neurological disorders.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - MIRA Pharmaceuticals
MIRA Pharmaceuticals develops drugs based on synthetic cannabinoid analogues. The company's book value is low. Its market capitalization is a pure bet by investors that its research will lead to approved drugs free of the side effects of natural marijuana.
Market to book capitalization ratio in a market segment - Narco farm
MIRA Pharmaceuticals is an early-stage biotech company developing cannabinoid-based drugs. The chart shows how the market values its research and potential to create a new class of drugs, offering a premium to its book value, which is primarily comprised of cash.
Market to book capitalization ratio for the market as a whole
MIRA Pharmaceuticals develops new cannabinoid-based drugs without psychoactive effects. The company's value depends almost entirely on the success of its clinical trials and its potential to transform the market. The chart shows how market valuation reflects faith in science and future patents, rather than current assets.
Debts of the company, segment and market as a whole
MIRA - Company debts MIRA Pharmaceuticals
For MIRA Pharmaceuticals, a company developing cannabinoid-based drugs, debt is the only way to fund research. This chart shows capital raising for preclinical and early clinical trials. These are high-risk investments in science that could lead to the development of a new class of drugs.
Market segment debts - Narco farm
MIRA Pharmaceuticals is a biopharmaceutical company developing cannabinoid-based drugs for the treatment of neurological and psychiatric disorders. Being in early research, the company has no revenue and relies entirely on equity capital. This chart reflects its financial position and ability to fund its research program.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio MIRA Pharmaceuticals
MIRA Pharmaceuticals is developing cannabinoid-based drugs. This chart reflects whether the company has raised debt financing. For an early-stage pharmaceutical company operating in such a highly specialized and regulated field, any debt is a high-risk factor that could impact its ability to complete its research.
Market segment debt to market segment book capitalization - Narco farm
MIRA Pharmaceuticals develops cannabinoid-based drugs, placing it at the intersection of biotechnology and the regulated industry. This chart for the pharmaceutical sector shows how companies fund their research in new and controversial areas of medicine. It provides context for assessing a company's financial risks and potential.
Debt to book value of all companies in the market
MIRA Pharmaceuticals is developing cannabinoid-based drugs for the treatment of neurological and psychiatric disorders. This chart, showing the debt-to-book value ratio, is important for assessing the investment climate in biotech. The market's willingness to finance companies with long development cycles determines MIRA's ability to raise capital.
P/E of the company, segment and market as a whole
P/E - MIRA Pharmaceuticals
MIRA Pharmaceuticals is developing drugs based on a synthetic marijuana analogue, devoid of psychoactive effects, for the treatment of neurological disorders. This chart reflects the company's confidence in its scientific potential. Its value indicates the willingness of investors to fund research that could lead to the creation of a new class of safe drugs.
P/E of the market segment - Narco farm
MIRA Pharmaceuticals is a biotech company. This chart shows the average P/E for the biotech sector. Comparing the company's P/E to this benchmark allows us to understand how highly the market values its approach to developing non-psychoactive cannabinoid analogues compared to the average prospects of other biotech companies.
P/E of the market as a whole
MIRA Pharmaceuticals is a pharmaceutical company developing synthetic cannabinoid analogues for the treatment of neurological and psychiatric disorders, but without the psychoactive effects. This chart shows the sentiment in the biotech sector. It helps understand how the market views MIRA's potential to offer a safer alternative to traditional cannabinoids and medicinal drugs.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company MIRA Pharmaceuticals
MIRA Pharmaceuticals is a preclinical company developing synthetic cannabinoid analogues for the treatment of neurological and psychiatric disorders. The graph reflects highly speculative expectations. Future revenue is entirely dependent on the success of research and the company's ability to bring its developments to clinical trials.
%20P%2FE%20MIRA%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-MIRA-Pharmaceuticals&v=1772679475753 "Chart of the company's future (projected) P/E MIRA Pharmaceuticals")
Future (projected) P/E of the market segment - Narco farm
MIRA Pharmaceuticals is a pharmaceutical company developing new drugs, potentially targeting the endocannabinoid system, for the treatment of neurological and psychiatric disorders. This chart shows its future profitability expectations, allowing us to assess how the market perceives its scientific approach.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Narco-farm&v=1772679475762 "Future (projected) P/E graph of the market segment - Narco farm")
Future (projected) P/E of the market as a whole
MIRA Pharmaceuticals is a company developing new synthetic cannabinoid-based drugs for the treatment of neurological and psychiatric disorders. Its valuation is a bet on scientific breakthroughs and regulatory changes in this field. It is not tied to general market forecasts, but rather driven by science.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772679475778 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit MIRA Pharmaceuticals
MIRA Pharmaceuticals is a biopharmaceutical company developing novel synthetic cannabinoid analogues aimed at treating neurological and psychiatric disorders, but without psychoactive effects. Being in the preclinical stage, it incurs significant R&D expenditures. This chart reflects its investments in creating the next generation of cannabis-based medicines.
Profit of companies in the market segment - Narco farm
MIRA Pharmaceuticals is a preclinical pharmaceutical company developing a new synthetic analogue of cannabidiol, which may offer therapeutic benefits without psychoactive effects. This chart shows the profitability of its segment. The company's R&D costs impact its current overall profitability, but its success could open a new direction in medical science.
Overall market profit
MIRA Pharmaceuticals is a preclinical company developing synthetic cannabinoid analogues for the treatment of neurological and psychiatric disorders. Its value is entirely dependent on the potential of its research and development. This graph reflects the real economy, while MIRA operates in the venture capital space, where success is determined by laboratory results.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company MIRA Pharmaceuticals
MIRA Pharmaceuticals is in the preclinical stage of developing a synthetic marijuana analogue that potentially lacks psychoactive side effects. This chart reflects analysts' long-term and speculative expectations. It demonstrates the market's faith in the company's scientific approach and its ability to successfully conduct expensive clinical trials.
%20profit%20of%20the%20company%20MIRA%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-MIRA-Pharmaceuticals&v=1772679475812 "Graph of future (projected) profit of the company MIRA Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Narco farm
MIRA Pharmaceuticals develops synthetic cannabinoid analogues for the treatment of neurological and psychiatric disorders. This chart shows profitability forecasts for the drug treatment segment of the pharmaceutical industry. It reflects expectations for the legalization and medical use of cannabinoids, where MIRA is working to create next-generation drugs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Narco-farm&v=1772679475821 "Graph of future (predicted) profits of companies in a market segment - Narco farm")
Future (predicted) profit of the market as a whole
MIRA Pharmaceuticals develops cannabinoid-based drugs. For a pharmaceutical company in the development stage, access to financing is key. The market's overall profit forecast influences investor sentiment: during periods of expected growth, investors are more inclined to invest in risky biotech projects like MIRA.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772679475832 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - MIRA Pharmaceuticals
MIRA Pharmaceuticals is a company developing new cannabinoid-based drugs. Being in the preclinical stage, it does not yet have revenue. The P/S will only become relevant after commercialization, at which point it will demonstrate how the market views its scientific approach and potential in the field of pharmaceutical cannabis.
P/S market segment - Narco farm
MIRA Pharmaceuticals is a company developing new synthetic cannabinoid analogues for the treatment of neurological and psychiatric disorders, while avoiding psychoactive side effects. This chart reflects market expectations regarding their scientific approach and future revenue potential in the cannabis pharmaceutical sector.
P/S of the market as a whole
MIRA Pharmaceuticals is in the preclinical stage of developing a new generation of psychedelic drugs without hallucinogenic effects. The company has no revenue, and its valuation is based on investors' belief in a future breakthrough in psychiatry. This chart, showing real revenue estimates, highlights the purely speculative nature of MIRA's valuation.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company MIRA Pharmaceuticals
MIRA Pharmaceuticals is a biopharmaceutical company developing a synthetic cannabidiol analogue devoid of psychoactive effects for the treatment of neurological and psychiatric disorders. This chart reflects investor expectations for future revenue from this potentially breakthrough drug if it proves its therapeutic value.
%20P%2FS%20MIRA%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-MIRA-Pharmaceuticals&v=1772679475883 "The graph of the company's future (projected) P/S MIRA Pharmaceuticals")
Future (projected) P/S of the market segment - Narco farm
MIRA Pharmaceuticals, Inc. is a pharmaceutical company developing a new, non-psychoactive cannabidiol-based drug for the treatment of neurological disorders and anxiety. This chart shows how the market perceives the future commercial potential of its unique product, comparing it to other pharmaceutical companies working in this field.
%20P%2FS%20market%20segment%20graph%20-%20Narco%20farm&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Narco-farm&v=1772679475892 "Future (projected) P/S market segment graph - Narco farm")
Future (projected) P/S of the market as a whole
MIRA Pharmaceuticals is a company developing new drugs for the treatment of neurological and psychiatric disorders, including synthetic cannabinoid analogues. This chart shows overall revenue projections, and MIRA illustrates how pharmaceutical research in complex and stigmatized areas can lead to breakthrough treatments.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772679475899 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales MIRA Pharmaceuticals
MIRA Pharmaceuticals is a preclinical pharmaceutical company focused on developing a new generation of psychedelic drugs without hallucinogenic effects. Currently, the company has no commercial products, so revenue is not shown on this graph. Future revenue depends on the success of research and partnerships.
Sales of companies in the market segment - Narco farm
MIRA Pharmaceuticals is a company developing new cannabinoid-based drugs. At this stage of development, its revenue, if any, may come from licensing agreements or grants. This chart allows investors to evaluate external financial support, which is critical for conducting research.
Overall market sales
MIRA Pharmaceuticals develops cannabinoid-based drugs. Like any pharmaceutical company in the development stage, its success depends on clinical trials and regulatory approvals. This timeline is unrelated to its core business. Furthermore, its specific sector is highly dependent on changes in cannabis legislation.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company MIRA Pharmaceuticals
MIRA Pharmaceuticals is a preclinical company developing synthetic cannabinoid analogues for the treatment of neurological and psychiatric disorders. Its revenue forecast is based entirely on future research success. This chart reflects analysts' highly speculative expectations for its research developments.
%20sales%20of%20the%20company%20MIRA%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-MIRA-Pharmaceuticals&v=1772679476028 "Schedule of future (projected) sales of the company MIRA Pharmaceuticals")
Future (projected) sales of companies in the market segment - Narco farm
MIRA Pharmaceuticals is a pharmaceutical company developing a new generation of synthetic cannabinoid analogues. This chart shows projected revenues for the entire addiction and neuroscience pharmaceutical sector. It allows one to assess the growth potential of the market for drugs that target the endocannabinoid system, which is important for the commercialization of MIRA's developments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Narco-farm&v=1772679476068 "Schedule of future (projected) sales of companies in the market segment - Narco farm")
Future (projected) sales of the market as a whole
MIRA Pharmaceuticals is a company developing cannabinoid-based drugs for the treatment of neurological and psychiatric disorders. Its future depends on the success of clinical trials and regulatory changes. This graph of both market expectations reflects the investment climate, which is important for funding risky early-stage biotech projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772679476088 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality MIRA Pharmaceuticals
MIRA Pharmaceuticals is a preclinical company developing novel synthetic cannabinoid analogues. This chart reflects its current status as a research-focused company. It demonstrates the company's investment in research, and its future ability to generate profits depends entirely on the success of its developments.
Market segment marginality - Narco farm
MIRA Pharmaceuticals is a biopharmaceutical company focused on developing new treatments for neurological and psychiatric disorders, including cannabinoid analogues. This chart shows the average profitability in the psychopharmacology sector. It provides context for assessing the potential profitability of the company's innovative drugs in this market.
Market marginality as a whole
MIRA Pharmaceuticals is a preclinical company developing cannabinoid analogues without psychoactive effects. Its value is based solely on expectations of future breakthroughs. This chart, showing the profitability of the real sector, has nothing to do with the venture world of biotech, where investors are betting on science.
Employees in the company, segment and market as a whole
Number of employees in the company MIRA Pharmaceuticals
MIRA Pharmaceuticals is a preclinical company developing cannabinoid analogues without psychoactive effects. Its extremely small team, consisting of a few scientists, focuses on early research. This graph illustrates the biotech startup model, where all value is concentrated in intellectual property and the scientific hypothesis.
Share of the company's employees MIRA Pharmaceuticals within the market segment - Narco farm
MIRA Pharmaceuticals is a company developing new synthetic cannabinoid analogues for the treatment of neurological and psychiatric disorders. This chart highlights its innovative scientific focus. It reflects the proportion of synthetic chemists and neurobiologists working at MIRA, working to create a new generation of drugs without psychoactive side effects.
Number of employees in the market segment - Narco farm
MIRA Pharmaceuticals is developing new synthetic cannabinoid analogues for the treatment of neurological and psychiatric disorders. This chart reflects activity in the cannabis-related pharmaceutical sector. The growing number of scientists in this field reflects the legalization and recognition of the therapeutic potential of cannabinoids.
Number of employees in the market as a whole
MIRA Pharmaceuticals, Inc. is a preclinical pharmaceutical company developing novel synthetic cannabinoid analogues. Biopharmaceutical research requires significant investment in scientific talent. This chart illustrates the overall labor market, where innovative companies like MIRA are laying the foundation for future medical breakthroughs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company MIRA Pharmaceuticals (MIRA)
MIRA Pharmaceuticals is in the R&D stage, and its value is based on expectations. This graph shows the "hope value" of one employee. The market values their pharmaceutical research potential, pricing each team member with the enormous value of future patents, potentially generating billions in revenue.
%20of%20the%20company%20MIRA%20Pharmaceuticals%20(MIRA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-MIRA-Pharmaceuticals-MIRA&v=1772679476171 "Chart of market capitalization per employee (in thousands of dollars) of the company MIRA Pharmaceuticals (MIRA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Narco farm
MIRA Pharmaceuticals develops cannabinoid-based drugs. It is an early-stage biotech company whose value is based on expectations. Its market value per employee reflects investors' faith in the scientific potential of its developments. A comparison with the industry demonstrates how unique and promising the market considers its approach.
%20by%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Narco-farm&v=1772679476175 "Market capitalization per employee (in thousands of dollars) by market segment - Narco farm")
Market capitalization per employee (in thousands of dollars) for the overall market
MIRA Pharmaceuticals is a company developing new synthetic cannabinoid analogues for the treatment of neurological and psychiatric disorders. This is at the forefront of pharmaceutical development. This chart reflects how the market perceives the scientific potential of a small team working on the creation of a new generation of drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772679476196 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company MIRA Pharmaceuticals (MIRA)
MIRA Pharmaceuticals is a preclinical biotech company developing synthetic cannabinoid analogues for the treatment of neurological disorders. This is pure science. This graph is deeply negative and shows how much capital is being burned for each scientist working on the creation of these new compounds.
%20Chart%20MIRA%20Pharmaceuticals%20(MIRA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-MIRA-Pharmaceuticals-MIRA&v=1772679476222 "Company Profit Per Employee (in thousands of dollars) Chart MIRA Pharmaceuticals (MIRA)")
Profit per employee (in thousands of dollars) in the market segment - Narco farm
MIRA Pharmaceuticals is in the preclinical stage of developing a new generation of synthetic cannabinoid analogues for the treatment of neurological and psychiatric disorders. This graph reflects the potential value of their research. It demonstrates the enormous profit potential of a breakthrough molecule created by a small team of scientists, compared to other pharmaceutical companies.
%20in%20the%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Narco-farm&v=1772679476226 "Chart of profit per employee (in thousands of dollars) in the market segment - Narco farm")
Profit per employee (in thousands of dollars) for the market as a whole
MIRA Pharmaceuticals is developing new treatments targeting neurological disorders and addictions, including cannabinoid-based drugs. It's an early-stage biotech company. The chart reflects R&D expenditure per scientist. There's no profit yet, so this metric reflects the "cost" of a team working on potential blockbusters.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772679476227 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee MIRA Pharmaceuticals (MIRA)
MIRA Pharmaceuticals is a company developing cannabinoid-based drugs. This schedule does not reflect commercial activity during the preclinical stage. No revenue per employee is normal. Future success will depend on trial results and regulatory approval.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-MIRA-Pharmaceuticals-MIRA&v=1772679476232 "Sales chart per company employee MIRA Pharmaceuticals (MIRA)")
Sales per employee in the market segment - Narco farm
MIRA Pharmaceuticals (MIRA) is a biopharmaceutical company developing new treatments for neurological and psychiatric disorders, including cannabinoid-based drugs. This chart shows the average revenue per employee in the pharmaceutical segment. For MIRA, which is in the R&D stage, comparison to this benchmark highlights their focus on science rather than current sales.
Sales per employee for the market as a whole
MIRA Pharmaceuticals is an early-stage biotech company developing drugs (including cannabinoid-based ones). Like other biotechs (AKTX, LIXT), there is no revenue. This metric is irrelevant and reflects only R&D costs. Investors look at scientific prospects, not current financial metrics.
Short shares by company, segment and market as a whole
Shares shorted by company MIRA Pharmaceuticals (MIRA)
MIRA Pharmaceuticals is a preclinical company trying to develop a new, non-addictive drug for the treatment of anxiety and depression (an alternative to opioids). This is a highly speculative bet. This chart illustrates the skepticism of the "bears," who believe the chances of success in psychiatry are slim and the company will run out of money.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-MIRA-Pharmaceuticals-MIRA&v=1772679476240 "Short Shares Chart for the Company MIRA Pharmaceuticals (MIRA)")
Shares shorted by market segment - Narco farm
MIRA Pharmaceuticals is an early-stage company attempting to create a THC (cannabis) analogue without psychoactive effects. This chart illustrates the pessimism across the sector. The growing short-selling of the industry is a bet that such drugs will never pass regulatory approval (for example, by the DEA). Investors doubt the therapeutic and commercial value of this approach, creating a climate of widespread mistrust for MIRA.
Shares shorted by the overall market
MIRA Pharmaceuticals develops cannabinoid-based drugs targeting neurological and mental health disorders. This is a speculative sector with high regulatory barriers. This chart illustrates the general fear. When investors are afraid, they are reluctant to get involved in "drug-pharma." The risks of legalization and failed clinical trials seem too high in a volatile market.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator MIRA Pharmaceuticals (MIRA)
MIRA Pharmaceuticals (MIRA) is a biotech company developing new drugs, including cannabis analogs, for the treatment of neurological disorders. This is a speculative area. This chart measures the strength of price movements. It helps determine when the stock is "overheated" (above 70) in anticipation of news or "oversold" (below 30) due to delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-MIRA-Pharmaceuticals-MIRA&v=1772679476262 "RSI 14 indicator chart for the company's stock MIRA Pharmaceuticals (MIRA)")
RSI 14 Market Segment - Narco farm
MIRA Pharmaceuticals (MIRA) is a biotech company working on developing a synthetic cannabinoid (a THC analog) that could offer therapeutic benefits without the psychoactive effects. This chart measures the collective sentiment in the Pharma/Cannabis sector. It shows when the entire industry is overhyped or oversold.
RSI 14 for the overall market
MIRA Pharmaceuticals (MIRA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MIRA (MIRA Pharmaceuticals)
MIRA Pharmaceuticals is a biotech company developing drugs based on cannabinoid analogues. Its goal is to develop a drug (MIRA-55) for anxiety and pain that *doesn't* cause psychoactive effects. This chart shows the speculative average price target from analysts based on their assessment of the company's R&D portfolio.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MIRA-MIRA-Pharmaceuticals&v=1772679476278 "A chart showing analyst consensus forecasts for the expected stock price. MIRA (MIRA Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price MIRA (MIRA Pharmaceuticals)
MIRA is a biopharmaceutical company developing synthetic cannabinoid analogues for the treatment of neurological disorders such as anxiety. This chart shows the difference between the market valuation and the consensus forecast. It highlights the potential experts see in this R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MIRA-MIRA-Pharmaceuticals&v=1772679476289 "A chart showing the difference between the consensus forecast and the actual stock price. MIRA (MIRA Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Narco farm
MIRA Pharmaceuticals is a biotech company trying to create "medical marijuana 2.0." It is developing a THC analogue for the treatment of neurological disorders, but without the psychoactive effects. This chart shows general expectations for the pharmaceutical sector. It reflects whether experts believe in the legalization and medical potential of cannabinoids.
Analysts' consensus forecast for the overall market share price
MIRA Pharmaceuticals is a biotech company developing cannabinoid-based drugs (marijuana analogs) for the treatment of anxiety and depression. This chart shows the overall market "risk appetite." For MIRA, which operates in the speculative "drug-medicine" sector, overall market optimism (risk appetite) is critical for funding clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index MIRA Pharmaceuticals
MIRA Pharma is a biotech company working at the intersection of neuroscience and cannabis. They are developing synthetic THC analogues (without psychoactive effects) aimed at treating anxiety and dementia. This chart is a clear indicator of their R&D, reflecting their progress in preclinical research and their speculative bet on medical cannabis.
AKIMA Market Segment Index - Narco farm
MIRA Pharmaceuticals (MIRA) is a biopharmaceutical company developing non-psychoactive drugs targeting cannabinoid receptors for the treatment of anxiety, depression, and neurological disorders. The chart shows the segment average, helping investors assess how MIRA's risks and potential compare to the industry average.
The AKIM Index for the overall market
MIRA Pharmaceuticals is a preclinical pharmaceutical company developing a synthetic THC analogue for the treatment of pain and anxiety. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative scientific story fits into the context of overall economic trends and interest in cannabinoids.
